1. Home
  2. Analysis
  3. Combivent-respimat
  4. Jakafi

Combivent respimat and Jakafi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Combivent respimat (albuterol sulfate; ipratropium bromide) and Jakafi (ruxolitinib phosphate). Common drug interactions include platelet count decreased among females and chest discomfort among males.

The phase IV clinical study analyzes what interactions people have when they take Combivent respimat and Jakafi. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Combivent respimat?

Combivent respimat has active ingredients of albuterol sulfate; ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 2,696 Combivent respimat users. Check the latest studies of Combivent respimat.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

On Jul, 06, 2026

15 people who take Combivent respimat and Jakafi together, and have interactions are studied.

Combivent respimat and Jakafi drug interactions.

What are the common drug interactions of Combivent Respimat and Jakafi, by gender? *:

female:

  1. Platelet count decreased
  2. Sleep talking (talking during sleeping)
  3. Teeth brittle (other half has a defect in the teeth)
  4. Contusion (a type of hematoma of tissue in which capillaries)
  5. Dry mouth
  6. Dysstasia (difficulty in standing)
  7. Loose tooth
  8. Muscle spasms (muscle contraction)
  9. Muscle strain (an injury to a muscle in which the muscle fibres tear)
  10. Myalgia (muscle pain)

male:

  1. Chest discomfort
  2. Dyspnoea (difficult or laboured respiration)

What are the common drug interactions of Combivent Respimat and Jakafi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Contusion (a type of hematoma of tissue in which capillaries)
  2. Dry mouth
  3. Teeth brittle (other half has a defect in the teeth)
  4. Dysstasia (difficulty in standing)
  5. Loose tooth
  6. Muscle spasms (muscle contraction)
  7. Muscle strain (an injury to a muscle in which the muscle fibres tear)
  8. Myalgia (muscle pain)
  9. Pain in extremity
  10. Platelet count decreased

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 5 people, 33.33%
  2. Myeloid Leukaemia (a type of cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 6.67%
  3. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 6.67%
  4. Immunodeficiency Common Variable: 1 person, 6.67%
  5. Blood Disorder: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Combivent respimat and Jakafi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Combivent respimat and Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Combivent respimat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Combivent respimat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Jakafi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on albuterol sulfate; ipratropium bromide and ruxolitinib phosphate (the active ingredients of Combivent respimat and Jakafi, respectively), and Combivent respimat and Jakafi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.